BUZZ-Filana rises after FDA lifts hold on epilepsy drug study

** Tuberous sclerosis complex is a rare genetic disorder that can cause tumors in several organs and seizures that are often difficult to control

** Simufilam is designed to modify filamin A, a protein that helps maintain cell structure and regulate signals within cells; the drug reduced seizure activity in two mouse studies

** Study will test two doses in 40 patients aged 12 to 55 across 13 US sites, with screening expected to begin by Q1 2027

** FLNA down 62.7% YTD, as of last close

** Shares of drug developer Filana Therapeutics FLNA.O rise 30% to 96 cents premarket

** Co says the US FDA lifted a clinical hold on its experimental drug simufilam

** Filana says this clears the way for a mid-stage study in patients with epilepsy linked to tuberous sclerosis complex